Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Chugai’s PNH Med, Takeda’s cTTP Therapy Now in Line for Japan Approval
Chugai Pharmaceutical’s paroxysmal nocturnal hemoglobinuria (PNH) treatment crovalimab sailed through the review of a key Japanese advisory panel on February 29, setting the stage for approval in the near future along with a batch of other medicines endorsed on the…
To read the full story
Related Article
- Chugai’s PNH Med, Takeda’s cTTP Therapy Up for Advisory Panel Review on Feb. 29
February 16, 2024
- Viatris Files Cystinosis Med in Japan
September 22, 2023
- Takeda Files cTTP Therapy ADAMTS-13 in Japan
August 18, 2023
- Meiji Seika Pharma Files GVHD Drug Belumosudil in Japan
June 28, 2023
- UCB Japan Seeks Lennox-Gastaut Syndrome Indication for Fintepla
June 28, 2023
- Chugai Files NDA for PNH Drug Crovalimab in Japan
June 15, 2023
REGULATORY
- Defense Chief Seeks MHLW Help Securing Drugs for SDF
September 9, 2026
- PMDA Generic GMP Inspections a Real-World Test to Stem Startup Risks: Official
September 8, 2026
- CEA Review Finds Past Decisions Sound, Sees Room for More Transparency
September 8, 2026
- MHLW Adds Pomalyst Generics to RevMate Safety Program
September 8, 2026
- Japan Extends Shelf Life of Stockpiled Xofluza to 9 Years
September 8, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…